Yamamoto K, Som P, Srivastava S C, Meinken G E, Brill A B
J Nucl Med. 1985 Jul;26(7):765-9.
High pancreatic affinity for 131I-labeled HIPDM was observed in mice and rats. Although the brain uptake of [131I]HIPDM is very fast, the pancreatic uptake is rather slow. The pancreas to liver ratios (per gram) were 5.08 +/- 0.52 in mice and 5.15 +/- 0.65 in rats at 2 hr and 7.05 +/- 0.53 in mice and 8.06 +/- 1.14 in rats at 5 hr after administration. These ratios are higher than those obtained with routinely used pancreatic agent [75Se]selenomethionine. An increase in liver uptake and decrease in pancreatic uptake was observed at higher dose of carrier HIPDM, which resulted in lower pancreas to liver ratios. HIPDM is a new type of compound which shows predilection for pancreas. Our results suggest that [123I]HIPDM might be a useful agent for pancreas imaging.
在小鼠和大鼠中观察到胰腺对131I标记的HIPDM具有高亲和力。虽然[131I]HIPDM在脑中的摄取非常迅速，但在胰腺中的摄取相当缓慢。给药后2小时，小鼠和大鼠的胰腺与肝脏重量比（每克）分别为5.08±0.52和5.15±0.65；5小时时，小鼠和大鼠的该比值分别为7.05±0.53和8.06±1.14。这些比值高于常规使用的胰腺显像剂[75Se]硒代蛋氨酸的相应比值。在较高剂量的载体HIPDM时，观察到肝脏摄取增加而胰腺摄取减少，这导致胰腺与肝脏的比值降低。HIPDM是一种对胰腺有偏好性的新型化合物。我们的结果表明，[123I]HIPDM可能是一种用于胰腺显像的有用试剂。
